AXSM EBITDA Growth
Axsome Therapeutics Inc · EBITDA Growth
AXSM EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported22.93%period ending
AXSM TTM EBITDA YoY % (-263.72% → 22.93%)
Year-over-year change
High-resolution chart · PNG
AXSM ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 22.9278% | |
| 34.3759% | |
| 39.1792% | |
| 29.1141% | |
| 23.4183% | |
| 8.1524% | |
| -21.5793% | |
| -60.8931% | |
| -80.1362% | |
| -102.8111% | |
| -28.6881% | |
| -24.8599% | |
| -17.2429% | |
| -5.0018% | |
| -41.022% | |
| -25.0292% | |
| -30.657% | |
| -40.4968% | |
| -23.2345% | |
| -22.4931% | |
| -15.6829% | |
| -6.9547% | |
| -49.485% | |
| -86.7013% | |
| -126.9153% | |
| -149.4525% | |
| -125.0296% | |
| -88.7019% | |
| -60.8378% | |
| -46.5972% | |
| -8.1406% | |
| 0.2764% | |
| 10.8971% | |
| 15.4455% | |
| -1.8925% | |
| -32.3196% | |
| -83.1336% | |
| -163.1333% | |
| -281.684% | |
| -158.816% | |
| -159.7354% | |
| -176.7175% | |
| -263.7249% |